Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use

Benralizumab is an IL-5 receptor alpha–directed cytolytic mAb that depletes eosinophils, reducing exacerbations and oral corticosteroid (OCS) use, and improves asthma control for patients with severe eosinophilic asthma (SEA). Data on response in patients previously treated with other biologic thera...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2022-06, Vol.10 (6), p.1534-1544.e4
Hauptverfasser:	Jackson, David J., Burhan, Hassan, Menzies-Gow, Andrew, Pfeffer, Paul, Nanzer, Alexandra, Garcia Gil, Esther, Morris, Tamsin, Tran, Trung N., Hirsch, Ian, Dube, Sabada
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthma Atopy Benralizumab Biologic Clinical outcomes Clinical trials Drug dosages Emergency medical care Fractional exhaled nitric oxide Health care Immunosuppressive agents Interleukin 5 Leukocytes (eosinophilic) Monoclonal antibodies Nitric oxide Oral corticosteroids Patient-reported outcomes Patients Questionnaires Real-world study Reimbursement Resource utilization Severe eosinophilic asthma Steroids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!